Vol. 3 No. 1 (2009)

Published: 11 June 2009

2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009

Abstracts

T-cell and natural killer-cell lymphomas An update based on the 2008 WHO classification

E.S. Jaffe

https://doi.org/10.4081/hmr.v3i1.521

377

PDF: 359
- PDF
First line therapy for peripheral T-cell lymphoma

D. Sibon

https://doi.org/10.4081/hmr.v3i1.522

255

PDF: 1354
- PDF
Treatment of natural killer/T-cell lymphoma

R Liang

https://doi.org/10.4081/hmr.v3i1.523

330

PDF: 1309
- PDF
The role of positron emission tomography in T-cell lymphoma and T-cell specific response criteria

BD Cheson

https://doi.org/10.4081/hmr.v3i1.524

301

PDF: 562
- PDF
Epigenetic approaches. Histone deacetylase inhibitors: vorinostat. A new treatment option for advanced cutaneous T-cell lymphoma

M Duvic

https://doi.org/10.4081/hmr.v3i1.525

342

PDF: 619
- PDF
Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma

HM Prince, M Prince

https://doi.org/10.4081/hmr.v3i1.526

433

PDF: 4655
- PDF
Activity of Belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma

F Foss, R Advani, K Hymes, B Pohlman, E Jacobsen, J McDonnell, A Lerner

https://doi.org/10.4081/hmr.v3i1.527

323

PDF: 396
- PDF
Gene expression profiling of peripheral T-cell lymphoma: from bench to bedside

PP Piccaluga, M Rossi, A Gazzola, MR Sapienza, C Mannu, S Righi, C Agostinelli, MT Sista, SA Pileri

https://doi.org/10.4081/hmr.v3i1.528

299

PDF: 398
- PDF
Angioimmunoblastic T-cell lymphoma: a tumor of follicular helper T cells derivation with clinical and pathological relevance

P Gaulard, Y-L Huang, C Thielen, L de Leval

https://doi.org/10.4081/hmr.v3i1.529

293

PDF: 998
- PDF
Anaplastic large cell lymphoma, ALK-positive and anaplastic large cell lymphoma ALK-negative

G Delsol, L Brugières, P Gaulard, E Espinos, L Lamant

https://doi.org/10.4081/hmr.v3i1.530

483

PDF: 1029
- PDF
Plitidepsin is active in peripheral T-cell lymphoma: a subset analysis from an ongoing multicenter phase II trial

C Ferme, MV Mateos, S Szyldergemajn, E Zucca, S Extremera, J Briones, G Alessandro, V Ribrag

https://doi.org/10.4081/hmr.v3i1.531

275

PDF: 255
- PDF
Monoclonal antibody therapy of T cell lymphoma: single agent trials of anti-CD2 (Siplizumab) and anti-CD4 (Humax-CD4)

JE Janik, D O’Mahony, TA Waldmann, JC Morris

https://doi.org/10.4081/hmr.v3i1.532

447

PDF: 533
- PDF
Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas

O Shonukan, AH Dantzig, S Kloeker-Rhoades, I Garcia-Ribas

https://doi.org/10.4081/hmr.v3i1.533

404

PDF: 473
- PDF
Forodesine

V Gandhi

https://doi.org/10.4081/hmr.v3i1.534

262

PDF: 385
- PDF
Pentostatin in peripheral T-cell lymphomas

C Dearden

https://doi.org/10.4081/hmr.v3i1.535

269

PDF: 622
- PDF
Preclinical evaluation of sorafenib against B- and T-cell lymphoma

N Schuelper, B Chapuy, T Relander, L Truemper, G Wulf

https://doi.org/10.4081/hmr.v3i1.536

265

PDF: 200
- PDF
Immune modulation as a treatment strategy in angioimmunoblastic T-cell lymphoma

R Advani

https://doi.org/10.4081/hmr.v3i1.537

268

PDF: 178
- PDF
M. Santucci Cutaneous T-cell lymphomas: histology

M Santucci

https://doi.org/10.4081/hmr.v3i1.538

222

PDF: 1720
- PDF
Cutaneous T-cell lymphoma, new insights

MB Wozniak, SM Rodriguez Pinilla, R Villuendas, M Herrera, PL Ortiz, MA Piris

https://doi.org/10.4081/hmr.v3i1.539

281

PDF: 244
- PDF
Zanolimumab (Humax-CD4), a fully human monoclonal antibody with significant clinical responses in cutaneous T-cell lymphoma

YH Kim

https://doi.org/10.4081/hmr.v3i1.540

360

PDF: 532
- PDF
Forodesine

EA Olsen

https://doi.org/10.4081/hmr.v3i1.541

244

PDF: 188
- PDF
Gemcitabine

M Tani, L Alinari, A Broccoli, E Derenzini, M Fina, L Gandolfi, E Marchi, C Pellegrini, V Stefoni, F Venturini, PL Zinzani

https://doi.org/10.4081/hmr.v3i1.542

274

PDF: 241
- PDF
Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: an update

S Pulini, S Rupoli, G Goteri, R Alterini, M Cantonetti, A Fabbri, P Quaglino, N Pimpinelli

https://doi.org/10.4081/hmr.v3i1.543

358

PDF: 466
- PDF
Innovative treatments: bexarotene

M Duvic

https://doi.org/10.4081/hmr.v3i1.544

265

PDF: 404
- PDF
Innovative treatments: bortezomib

PL Zinzani

https://doi.org/10.4081/hmr.v3i1.545

225

PDF: 215
- PDF
Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma

C Querfeld, TM Kuzel, J Guitart, ST Rosen

https://doi.org/10.4081/hmr.v3i1.546

432

PDF: 665
- PDF
NOTCH1: a therapeutic target for T cell acute lymphoblastic leukemia/lymphoma

V Tosello, A Ferrando

https://doi.org/10.4081/hmr.v3i1.547

247

PDF: 484
- PDF
Pediatric T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma therapy

A Pession, R Masetti, R Rondelli

https://doi.org/10.4081/hmr.v3i1.548

383

PDF: 621
- PDF
T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma: therapy in adults

M Bonifacio, O Perbellini, G Pizzolo

https://doi.org/10.4081/hmr.v3i1.549

320

PDF: 2904
- PDF
Prognostic factors in cutaneous T-cell lymphoma

R Willemze

https://doi.org/10.4081/hmr.v3i1.550

291

PDF: 1648
- PDF
High-dose therapy and autotransplantation in peripheral T-cell lymphoma and cutaneous T-cell lymphoma

P Reimer

https://doi.org/10.4081/hmr.v3i1.551

235

PDF: 419
- PDF
Allogeneic transplantation for peripheral and cutaneous T-cell lymphomas

P Corradini, A Dodero, G Lambertenghi-Deliliers, F Onida

https://doi.org/10.4081/hmr.v3i1.552

301

PDF: 234
- PDF

Current Issue

Vol. 3 No. 1 (2009)

Abstracts

T-cell and natural killer-cell lymphomas An update based on the 2008 WHO classification

First line therapy for peripheral T-cell lymphoma

Treatment of natural killer/T-cell lymphoma

The role of positron emission tomography in T-cell lymphoma and T-cell specific response criteria

Epigenetic approaches. Histone deacetylase inhibitors: vorinostat. A new treatment option for advanced cutaneous T-cell lymphoma

Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma

Activity of Belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma

Gene expression profiling of peripheral T-cell lymphoma: from bench to bedside

Angioimmunoblastic T-cell lymphoma: a tumor of follicular helper T cells derivation with clinical and pathological relevance

Anaplastic large cell lymphoma, ALK-positive and anaplastic large cell lymphoma ALK-negative

Plitidepsin is active in peripheral T-cell lymphoma: a subset analysis from an ongoing multicenter phase II trial

Monoclonal antibody therapy of T cell lymphoma: single agent trials of anti-CD2 (Siplizumab) and anti-CD4 (Humax-CD4)

Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas

Forodesine

Pentostatin in peripheral T-cell lymphomas

Preclinical evaluation of sorafenib against B- and T-cell lymphoma

Immune modulation as a treatment strategy in angioimmunoblastic T-cell lymphoma

M. Santucci Cutaneous T-cell lymphomas: histology

Cutaneous T-cell lymphoma, new insights

Zanolimumab (Humax-CD4), a fully human monoclonal antibody with significant clinical responses in cutaneous T-cell lymphoma

Forodesine

Gemcitabine

Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: an update

Innovative treatments: bexarotene

Innovative treatments: bortezomib

Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma

NOTCH1: a therapeutic target for T cell acute lymphoblastic leukemia/lymphoma

Pediatric T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma therapy

T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma: therapy in adults

Prognostic factors in cutaneous T-cell lymphoma

High-dose therapy and autotransplantation in peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Allogeneic transplantation for peripheral and cutaneous T-cell lymphomas

Categories